116 related articles for article (PubMed ID: 12322838)
1. p53 tumor suppressor gene mutation in ovarian cancer in Thai patients.
Neungton N; Neungton S; Leelaphatanadit C; Dangrat C; Soiampornkul R
J Med Assoc Thai; 2002 Jun; 85(6):658-67. PubMed ID: 12322838
[TBL] [Abstract][Full Text] [Related]
2. [Detection and sequence analysis of the p53 gene mutation in epithelial ovarian cancer].
Guan X; Lang J; Bian M
Zhonghua Fu Chan Ke Za Zhi; 1998 Mar; 33(3):165-7. PubMed ID: 10682487
[TBL] [Abstract][Full Text] [Related]
3. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
[TBL] [Abstract][Full Text] [Related]
4. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F
Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996
[TBL] [Abstract][Full Text] [Related]
6. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
8. The role of p53 mutation in the carcinomas arising from endometriosis.
Akahane T; Sekizawa A; Purwosunu Y; Nagatsuka M; Okai T
Int J Gynecol Pathol; 2007 Jul; 26(3):345-51. PubMed ID: 17581423
[TBL] [Abstract][Full Text] [Related]
9. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
Høgdall EV; Ryan A; Kjaer SK; Blaakaer J; Christensen L; Bock JE; Glud E; Jacobs IJ; Høgdall CK
Cancer; 2004 Jun; 100(11):2387-95. PubMed ID: 15160342
[TBL] [Abstract][Full Text] [Related]
10. P53 mutations in tissue from Danish ovarian cancer patients: from the Danish "MALOVA" ovarian cancer study.
Høgdall EV; Kjaer SK; Blaakaer J; Christensen L; Glud E; Vuust J; Høgdall CK
Gynecol Oncol; 2006 Jan; 100(1):76-82. PubMed ID: 16183105
[TBL] [Abstract][Full Text] [Related]
11. Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease.
Kupryjanczyk J; Thor AD; Beauchamp R; Poremba C; Scully RE; Yandell DW
Mod Pathol; 1996 Mar; 9(3):166-73. PubMed ID: 8685209
[TBL] [Abstract][Full Text] [Related]
12. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
13. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
14. P53 mutation does not affect prognosis in ovarian epithelial malignancies.
Fallows S; Price J; Atkinson RJ; Johnston PG; Hickey I; Russell SE
J Pathol; 2001 May; 194(1):68-75. PubMed ID: 11329143
[TBL] [Abstract][Full Text] [Related]
15. [Mutations of p53 gene exons 5 to 8 in human ovarian cancer and its clinical significance].
You Z; Guo Y; Wen H
Zhonghua Fu Chan Ke Za Zhi; 1996 Nov; 31(11):660-3. PubMed ID: 9387525
[TBL] [Abstract][Full Text] [Related]
16. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin.
Ueno Y; Enomoto T; Otsuki Y; Sugita N; Nakashima R; Yoshino K; Kuragaki C; Ueda Y; Aki T; Ikegami H; Yamazaki M; Ito K; Nagamatsu M; Nishizaki T; Asada M; Kameda T; Wakimoto A; Mizutani T; Yamada T; Murata Y
Cancer Lett; 2006 Sep; 241(2):289-300. PubMed ID: 16459017
[TBL] [Abstract][Full Text] [Related]
18. Is it possible to diagnose malignancy from fluid in cystic ovarian tumors?
Yamada R; Maeda N; Oguri H; Adachi Y; Takeuchi T; Furihata M; Fukaya T
Eur J Obstet Gynecol Reprod Biol; 2013 Nov; 171(1):96-100. PubMed ID: 24017961
[TBL] [Abstract][Full Text] [Related]
19. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma.
Leitao MM; Soslow RA; Baergen RN; Olvera N; Arroyo C; Boyd J
Gynecol Oncol; 2004 May; 93(2):301-6. PubMed ID: 15099937
[TBL] [Abstract][Full Text] [Related]
20. Geographical variations in TP53 mutational spectrum in ovarian carcinomas.
Dansonka-Mieszkowska A; Ludwig AH; Kraszewska E; Kupryjańczyk J
Ann Hum Genet; 2006 Sep; 70(Pt 5):594-604. PubMed ID: 16907706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
